Skip to main content

Table 1 Patients’ and treatment characteristics (n = 20)

From: Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes

Category

Distribution and%

Age (median, range)

61 (34–77)

2009 FIGO stage

 

  IIIA

7 (35%)

  IIIC

5 (25%)

   IIIC1

2 (10%)

   IIIC2

3 (15%)

  IVB

7 (35%)

  No classification available *

1 (5%)

Histology

 

  Endometrioid (pure)

13 (65%)

  Papillary serous (pure)

4 (20%)

  Papillary serous (mixed)

3 (15%)

Grade

 

  1

3 (15%)

  2

7 (35%)

  3

10 (50%)

Nodal status

 

  pN0

11 (55%)

  pN+

6 (30%)

  pNx

3 (15%)

Peritoneal cytology

 

  Positive or suspicious for malignant cells

15 (75%)

  Negative

4 (20%)

  Not done

1 (5%)

SURGERY

 

  Surgical approach

 

   Laparotomy

15 (75%)

   Laparoscopy

5 (25%)

  Lymph node dissection performed

17 (85%)

   Pelvic only

8 (40%)

   Pelvic + PA

9 (45%)

  Total number of dissected LN (median, range)

18 (3–46)

CHEMOTHERAPY

 

  Number of cycles (received/planned)

 

   0/6 cycles

2 (10%)

   3/3 cycles

2 (10%)

   4/6 cycles

1 (5%)

   5/6 cycles

1 (5%)

   6/6 cycles

14 (70%)

  Drug combination (n = 18)

 

   TP

14 (78%)

   TAP

4 (22%)

RADIOTHERAPY

 

  WAI total dose (median, range)

 

   Total dose (Gy)

27.5 (20–30)

   Daily dose (Gy)

1.25 (1.0 - 1.25

  Additional volume (boost)

 

   Pelvic only

7 (35%)

   Pelvic + PA

2 (10%)

  Cumulative total dose(median, range)

 

   Pelvis (Gy)

46.7 (44.8 - 48)

   PA (Gy)

46.7 (44.8 - 55.7)

  Vaginal cuff brachytherapy

17 (85%)

  Dose (median, range)

 

  Total dose (Gy)

18 (13–21)

  Number of fractions

3 (3–5)

TIMING (median, range)

 

  Between surgery and chemo start (days)

24 (9–48)

  Between end of chemo and RT start (days)

48 (21–104)

  Between surgery and completion of all treatments (months)

5.7 (1.5 - 7.6)

  Duration of RT (elapsed days)

35 (11–55)

  1. *multifocal cancer arising from endometriosis.
  2. Abbreviations: Chemo Chemotherapy, LN Lymph nodes, PA Para-aortic, RT Radiotherapy, TP Paclitaxel (175 mg/m2) and Carboplatin (Area under the Curve [AUC] 5); TAP = Paclitaxel (175 mg/m2), Doxorubicin (45 mg/m2) and Carboplatin (AUC5).